Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, 18 years or older
Histologically or cytologically confirmed adenocarcinoma of the pancreas
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Requirements for prior therapy as outlined below:
* Enrollment into Regimen A: received no more than 1 prior chemotherapy regimen for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy)
* Enrollment into Regimen B: received no prior chemotherapy for advanced or metastatic disease (not including neoadjuvant and/or adjuvant therapy)
Adequate renal, hepatic, and bone marrow function without blood product or hematopoietic growth factor support:
Able to swallow and retain oral medication
You may not be if
Any known contraindications to the use of gemcitabine (for enrollment in Regimen A or B) or nab-paclitaxel (for enrollment into Regimen B).
Evidence of uncontrolled brain metastases or history of uncontrolled seizures.
Subjects who participated in any other study in which receipt of an investigational study drug occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.
Current or previous other malignancy within 2 years of study entry, except cured basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or other noninvasive malignancy without sponsor approval.
Inability to swallow food or any condition of the upper GI tract that precludes administration of oral medications.
Recent (≤ 3 months) history of partial or complete bowel obstruction.
Unwilling to be transfused with blood components.
Known history of Hepatitis B or C infection or HIV infection.
Presence of ≥ Grade 2 neuropathy
Clareo Health | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors
